摘要
Heart failure (HF) is a common disease associated with increasing age. B-type natriuretic peptide (BNP), is a cardiac neurohormone, and is released as prepro BNP and then enzyrnatically cleaved to the Ntenninal-proBNP (NT-proBNP) and BNP upon ventricular myocyte stretch. Blood measurements of BNP have been used to identify patients with I-IF. The BNP assay is currently used as a diagnostic and prognostic aid in HF. In general, a BNP level below 100 pg/mL excludes acutely decompensated HF and levels ＞ 500 pg/ml indicate decompensation. Recombinant human BNP (hBNP, nesiritide) is an approved intravenous treatment for acute,decompensated -HF. Nesiritide given in supraphysiologic doses causes vasodilation, natriuresis, diuresis, and improved symptoms over the course of a 48-hour infusion. This paper will sort out the literature concerning the use of this peptide both as a diagnostic test and as an intravenous therapy.
Heart failure (HF) is a common disease associated with increasing age.B-type natriuretic peptide (BNP),is a cardiac neurohormone,and is released as prepro BNP and then enzymatically cleaved to the N- terminal-proBNP (NT-proBNP) and BNP upon ventricular myocyte stretch.Blood measurements of BNP have been used to identify patients with HF.The BNP assay is currently used as a diagnostic and prognostic aid in HF.In general,a BNP level below 100 pg/mL excludes acutely decompensated HF and levels > 500 pg/ml indicate decomponsation.Recombinant human BNP (hBNP,nesifitide) is an approved intravenous treatment for acute, decomponsated HF.Nesiritide given in supraphysiologic doses causes vasedilation,natriuresis,diuresis,and improved symptoms over the course of a 48-hour infusion.This paper will sort out the literature concerning the use of this peptide both as a diagnostic test and as an intravenous therapy.(J Cetiatr Cardiol 2004;1:21-28.)
